Circadian Rhythm of Blood Pressure in Congestive Heart Failure and Effects of ACE Inhibitors

References

• Todd PAR, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinatic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986;31:198–248.
   PubMed Web of Science ®Google Scholar
• Lacker M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe heart failure. Ann Intern Med 1987;106:346–54.
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429–35.
   PubMed Web of Science ®Google Scholar
• Giles TD, Katz R, Sullivan JM, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989; 13: 1240–7.
   PubMed Web of Science ®Google Scholar
• Jessup M. Angiotensin-converting enzyme inhibitors: are there significant clinical differences? J Am Coll Cardiol 1989;13:1248–50.
   PubMed Web of Science ®Google Scholar
• Tjon-A-Meeuw L, Hess OM, Greminger P, Maire R, Jenni R, Krayenbiihl HP. Vergleich von Enalapril und Captopril in der Behandlung der chronischen Herzinsuffizienz. Z Kardiol 1990;79:429–35.
   PubMedGoogle Scholar
• Fyhrquist F, Forslund T, Immonen I, Tikkanen I, Grdnhagen-Riska C, Hortling L. Renin, renin substrate, angiotensin 11, and vasopressin in plasma during treatment with captopril in hypertension and heart failure. Acta Med Scand 1983;677:110–4.
   Google Scholar
• Schuster VL, Seldin DW. Renal clearance. In: Seldin DW, Giebisch G, eds. The kidney: physiology and pathophysiology. New York: Raven Press, 1985:365–96.
   Google Scholar
• Hackenthal E, Hackenthal R, Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin A comparative enzymatic study of angiotensin-forming enzymes. Biochem Biophys Acta 1978;522:574–88.
   PubMed Web of Science ®Google Scholar
• Mattes A, Witte K, Hohmann W, Lemmer B. PHARMFIT-a non-linear fitting program forpharmacology. Chronobiol Int (in press).
   Google Scholar
• Meyer-Saballek W, Schulte K-L, Gotzen R. Technical possibilities and limits of indirect automatic twenty-four-hour blood pressure devices. J Hum Hypertens 1989;7(suppl 3):S21-4.
   Google Scholar
• Weber MA. Whole-day blood pressure. Hypertension 1988; 11 :288-98.
   Web of Science ®Google Scholar
• Meyer-Seballek W, Schulte KL, Distler A, Gotzen R. Technische Mooglichkeiten und Grenzen der ambulaten 24-h-Blutdruckmessung (ABDM). Z Kardrol 1991;8O(suppl 1): 1–7.
   Google Scholar
• Graettinger WF, Lipson JL, Cheung DG, Weber MA. Validation of portable nonivasive blood pressure monitoring devices: comparisons with intra-arterial and sphygmomanometer measurements. Am Heart J 1988;116:1155–60.
   PubMed Web of Science ®Google Scholar
• Parati G, Pomodossi G, Casadei R, et al. Ambulatory blood pressure monitoring does not interface with the haemodynamic effects of sleep. J Hypertens 1985;3(suppl 2): s 107–9.
   Google Scholar
• Mancia G, Parati G. Experience with 24-hour ambulatory blood pressure monitoring in hypertension. Am Heart J 1988;116:1134–40.
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. Br Heart J 1984;52:530–5.
   PubMedGoogle Scholar
• Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983;67:807–16.
   PubMed Web of Science ®Google Scholar
• Cannon PJ. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755–63.
   PubMed Web of Science ®Google Scholar
• Captopril-Digoxin Multicenter Research Group. Vergleich der Wirkungen einer Behandlung mit Captopril und Dogoxin bei Patienten mit leichter bis mittelschwerer Herzinsuffzienz. JAMA 1988;259:539–44.
   PubMed Web of Science ®Google Scholar
• Creager MA, Massie BM, Faxon DP, et al. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardioi 1985;6:163–70.
   PubMed Web of Science ®Google Scholar
• Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol 1985;s: 101–7.
   Google Scholar
• Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomised double-blind study. Circulation 1984;70:271–8.
   PubMed Web of Science ®Google Scholar
• Francis GS, Rucinska EJ. Long-term once-a-day versus twice-a-day regimen of enalapril for congestive heart failure. Am J Cardiol 1989;63:17D-21.
   Google Scholar
• Verdecchia P, Schillaci G, Guemeri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990;81:528–36.
   PubMed Web of Science ®Google Scholar
• Drayer JIM, Weber MA, Nakamura DK. Automated ambulatory blood pressure monitoring: a study in age-matched normotensive and hypertensive men. Am Heart J 1985;109:1334–8.
   PubMed Web of Science ®Google Scholar
• Parati G, Ravogli A, Trazzi S, et al. Balanced 24-hour blood pressure control by angiotensin-converting enzyme inhibitors administered once daily. J Hum Hypertens 1989;3:3–9.
   PubMed Web of Science ®Google Scholar
• Weber MA, Drayer JIM, Nakamura DK, Wyle FA. The circadian blood pressure pattern in ambulatory normal subjects. Am J Cardiol 1984;54:115–9.
   PubMed Web of Science ®Google Scholar
• Lemmer B. Temporal aspects of the effects of cardiovascular active drugs in humans. In: Lemmer B, ed. Chronopharmacology: cellular and biochemical interactions. New York, Basel: Marcel Dekker, Inc., 1989525–41.
   Google Scholar
• Caruana MP, Lahiri A, Cashman PMM, Altman DG, Raftery EB. Effects of chronic congestive heart failure secondary to coronary artery disease on the circadian rhythm of blood pressure and heart rate. Am J Cardiol 1988;62:755–9.
   PubMed Web of Science ®Google Scholar
• Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285:877–83.
   PubMed Web of Science ®Google Scholar
• Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913–9.
   PubMed Web of Science ®Google Scholar
• Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615–21.
   PubMed Web of Science ®Google Scholar
• Furlan R, Guzzetti S, Crivellaro W, et al. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities an ambulatory subjects. Circulation 1990;81:537–47.
   PubMed Web of Science ®Google Scholar
• Lemmer B. Temporal aspects of the regulation of the sympathetic nervous system in the rat. In: Lemmer B, ed. Chronopharmacology: cellular and biochemical interactions. New York, Basel: Marcel Dekker, Inc., 1989:477–508.
   Google Scholar
• Weber MA. Automated blood pressure monitoring: a new dimension in diagnosis. Mayo Clin Proc 1988;63:1151–3.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (First of two parts). N Engl J Med 1977:297:27-31.
   Web of Science ®Google Scholar
• Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med 1977:297:254-8.
   Web of Science ®Google Scholar
• Sturani A, Chiarini C, Esposti ED, Santoro A, Zuccala A, Zucchelli P. Captopril. N Engl J Med 1982;307:59–60.
   Google Scholar
• Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847–53.
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77(suppl 1): I-4-13.
   Google Scholar
• Unger T, Ganten D, Lang RE, Scholkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK42 I, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984;6:872–80.
   PubMed Web of Science ®Google Scholar
• Jin M, Wilhelm MJ, Lang RE, Lindpainter K, Ganten D. Endogenous tissue renin-angiotensin systems. From molecular biology to therapy. Am J Med 1988; 84 (suppl 3A): 28–36.
   PubMedGoogle Scholar
• Cushman DW, Wang RFL, Fung WC, et al. Comparison in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989;28:115s-31.
   Google Scholar
• Osterziel KJ, Dietz R, Kiibler W. Therapie der Herzinsuffizienz mit ACE-Hemmern: EinfluB auf die Nierenfunktion. Dtsch Med Wochenschr 1989;114:1082–5.
   PubMedGoogle Scholar
• Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol 1987;60:179–83.
   PubMed Web of Science ®Google Scholar
• Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977;233:F366–72.
   PubMed Web of Science ®Google Scholar
• Ischikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984;55:669–75.
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 1986;74:766–74.
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Medina N, Yushak M, Kessler P, Gottlieb SS. Influence of diabetes mellitus on the hemodynamic and clinical responses to converting-enzyme inhibition in severe chronic heart failure. J Am Con Cardiol 1987;9: 120A.
   Web of Science ®Google Scholar